Piperacillin-tazobactam: prospects for use in real-world practice
https://doi.org/10.37489/2782-3784-myrwd-36
EDN: CUYJRQ
Abstract
A review of the literature concerning the efficacy and safety of combined anti-pseudomonas protected ureidopenicillin piperacillin/tazobactam usage. Randomized clinical trials and their meta-analysis have demonstrated that piperacillin/ tazobactam among non-carbapenem β-lactams is an equally effective alternative to carbapenems in the treatment of severe infections, including those caused by extended-spectrum β-lactamase producing strains, regardless of the infection locus. It can be used in cases of carbapenem de-escalation if it is necessary. The use of this antimicrobial therapy strategy is justified not only from a clinical, but also from an economic point of view.
About the Author
Yu. M. Gomon
First St. Petersburg State Medical University named after academician I.P. Pavlov of the Ministry of Health of the Russian Federation ; Hospital of the Holy Great Martyr George,
Russian Federation
Russian Federation
Gomon Yulia M. — doctor of medical science, professor of the department of Clinical Pharmacology and Evidence-Based Medicine
RSCI AuthorID: 835831
St. Petersburg
References
1. Устойчивость к антимикробным препаратам. Информационный бюллетень ВОЗ. 2019. Режим доступа: https://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_R5-ru.pdf (Дата доступа: 20.09.2029).
2. Chou CH, Lai YR, Chi CY, Ho MW, Chen CL, Liao WC, Ho CM, Chen YA, Chen CY, Lin YT, Lin CD, Lai CH. Long-Term Surveillance of Antibiotic Prescriptions and the Prevalence of Antimicrobial Resistance in Non-Fermenting Gram-Negative Bacilli. Microorganisms. 2020 Mar 12;8(3):397. doi: 10.3390/microorganisms8030397. PMID: 32178340; PMCID: PMC7142802.
3. The Lancet Infectious Diseases. Antimicrobial resistance through the looking-GLASS. Lancet Infect Dis. 2023 Feb;23(2):131. doi: 10.1016/S1473-3099(23)00012-9. PMID: 36707218.
4. Butler MS, Gigante V, Sati H, Paulin S, Al-Sulaiman L, Rex JH, Fernandes P, Arias CA, Paul M, Thwaites GE, Czaplewski L, Alm RA, Lienhardt C, Spigelman M, Silver LL, Ohmagari N, Kozlov R, Harbarth S, Beyer P. Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0199121. doi: 10.1128/ AAC.01991-21. Epub 2022 Jan 10. PMID: 35007139; PMCID: PMC8923189.
5. Whiles BB, Deis AS, Simpson SQ. Increased Time to Initial Antimicrobial Administration Is Associated With Progression to Septic Shock in Severe Sepsis Patients. Crit Care Med. 2017 Apr;45(4):623-629. doi: 10.1097/ CCM.0000000000002262. PMID: 28169944; PMCID: PMC5374449.
6. Seok H, Song J, Jeon JH, Choi HK, Choi WS, Moon S, Park DW. Timing of antibiotics in septic patients: a prospective cohort study. Clin Microbiol Infect. 2020 Nov;26(11):1495-1500. doi: 10.1016/j. cmi.2020.01.037. Epub 2020 Feb 14. PMID: 32062049.
7. Klein EY, Milkowska-Shibata M, Tseng KK, Sharland M, Gandra S, Pulcini C, Laxminarayan R. Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000-15: an analysis of pharmaceutical sales data. Lancet Infect Dis. 2021 Jan;21(1):107-115. doi: 10.1016/S1473-3099(20)30332-7. Epub 2020 Jul 24. PMID: 32717205.
8. Захаренков И.А., Рачина С.А., Козлов Р.С., Белькова Ю.А. Потребление системных антибиотиков в России в 2017-2021 гг.: основные тенденции. Клиническая микробиология и антимикробная химиотерапия. 2022;24(3):220-225.
9. Гомон Ю.М., Колбин А.С., Арепьева М.А. с соавт. Потребление антимикробных препаратов в РФ (2008-2022 гг.): фармакоэпидемиологическое исследование. Клиническая микробиология и антимикробная химиотерапия. 2023. В печати
10. MacVane SH, Kuti JL, Nicolau DP. Prolonging β-lactam infusion: a review of the rationale and evidence, and guidance for implementation. Int J Antimicrob Agents. 2014 Feb;43(2):105-13. doi: 10.1016/j.ijantimicag.2013.10.021. Epub 2013 Nov 24. PMID: 24359838.
11. Schoonover LL, Occhipinti DJ, Rodvold KA, Danziger LH. Piperacillin/tazobactam: a new beta-lactam/ beta-lactamase inhibitor combination. Ann Pharmacother. 1995 May;29(5):501-14. doi: 10.1177/10600280 9502900510. PMID: 7655135.
12. Perry CM, Markham A. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs. 1999 May;57(5):805-43. doi: 10.2165 /00003495-199957050-00017. PMID: 10353303.
13. Яковлев С.В. Комбинированная лекарственная форма пиперациллина с тазобактамом — тазоцин. Антибиотики и Химиотерапия. 1997;42(2):5-16.
14. Государственный реестр лекарственных средств. https://grls.rosminzdrav.ru/default.aspx
15. Кузьменков А.Ю., Виноградова А.Г., Трушин И.В., Эйдельштейн М.В., Авраменко А.А., Дехнич А.В., Козлов Р.С. AMRmap — система мониторинга антибиотикорезистентности в России. Клиническая микробиология и антимикробная химиотерапия. 2021;23(2):198-204. DOI: 10.36488/cmac.2021.2. 198-204.
16. «Диагностика и антимикробная терапия инфекций, вызванных полирезистентными штаммами микроорганизмов (обновление 2022 г.)». Режим доступа: https://association-ar.ru/wp-content/uploads/2022/03/%D0%9C%D0%A0-%D0%90%D0%91%D0%A2.pdf (Дата доступа: 20.09.2023).
17. Sörgel F, Kinzig M. Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections. Eur J Surg Suppl. 1994;(573):39-44. PMID: 7524794.
18. Erasmo AA, Crisostomo AC, Yan LN, Hong YS, Lee KU, Lo CM. Randomized comparison of piperacillin/ tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection. Asian J Surg. 2004 Jul;27(3):227-35. doi: 10.1016/S1015-9584(09)60039-7. PMID: 15564167.
19. Figuera A, Rivero N, Pajuelo F, Font P, Leyra F, de La Cámara R, Arranz R, María Fernández Rañada J. Estudio comparativo de piperacilina/tazobactam frente a imipenem/cilastatina en la neutropenia febril (1994- 1996) [Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994- 1996)]. Med Clin (Barc). 2001 May 5;116(16):610-1. Spanish. doi: 10.1016/s0025-7753(01)71921-5. PMID: 11412645.
20. Ito I, Kadowaki S, Tanabe N, Haruna A, Kase M, Yasutomo Y, Tsukino M, Nakai A, Matsumoto H, Niimi A, Chin K, Ichiyama S, Mishima M. Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: comparison with imipenem/ cilastatin. Pulm Pharmacol Ther. 2010 Oct;23(5):403- 10. doi: 10.1016/j.pupt.2010.05.007. Epub 2010 Jun 2. PMID: 20561917.
21. Naber KG, Savov O, Salmen HC. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. Int J Antimicrob Agents. 2002 Feb;19(2):95-103. doi: 10.1016/s0924-8579(01)00481-2. PMID: 11850161.
22. Saltoglu N, Dalkiran A, Tetiker T, Bayram H, Tasova Y, Dalay C, Sert M. Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. Clin Microbiol Infect. 2010 Aug;16(8):1252-7. doi: 10.1111/j.1469-0691.2009.03067.x. Epub 2009 Oct 14. PMID: 19832720.
23. Titov I, Wunderink RG, Roquilly A, Rodríguez Gonzalez D, David-Wang A, Boucher HW, Kaye KS, Losada MC, Du J, Tipping R, Rizk ML, Patel M, Brown ML, Young K, Kartsonis NA, Butterton JR, Paschke A, Chen LF. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/ Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). Clin Infect Dis. 2021 Dec 6;73(11):e4539-e4548. doi: 10.1093/cid/ ciaa803. PMID: 32785589; PMCID: PMC8662781.
24. Munch MW, Granholm A, Jonsson AB, Sjövall F, Helleberg M, Hertz FB, Andersen JS, Steensen M, Achiam MP, Perner A, Møller MH. Piperacillin/tazobactam versus carbapenems in patients with severe bacterial infections: A systematic review with meta-analysis. Acta Anaesthesiol Scand. 2023 Aug;67(7):853-868. doi: 10.1111/aas.14239. Epub 2023 Mar 28. PMID: 36919866.
25. Sun Y, Liu Y, Wang J, Cui C. The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock. Heliyon. 2023 May 20;9(6):e16542. doi: 10.1016/j.heliyon.2023.e16542. PMID: 37292309; PMCID: PMC10245158.
26. Karaiskos I, Giamarellou H. Carbapenem-Sparing Strategies for ESBL Producers: When and How. Antibiotics (Basel). 2020 Feb 5;9(2):61. doi: 10.3390/antibiotics9020061. PMID: 32033322; PMCID: PMC7167803.
27. Tamma PD, Rodriguez-Bano J. The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections. Clin Infect Dis. 2017 Apr 1;64(7):972-980. doi: 10.1093/cid/cix034. PMID: 28362938; PMCID: PMC5848369.
28. MacGowan A. Revisiting Beta-lactams — PK/PD improves dosing of old antibiotics. Curr Opin Pharmacol. 2011 Oct;11(5):470-6. doi: 10.1016/j.coph.2011.07.006. Epub 2011 Aug 19. PMID: 21862409.
29. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998 Jul;27(1):10-22. doi: 10.1086/514622. PMID: 9675443.
30. Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011 Mar;86(3):250-9. doi: 10.4065/mcp.2010.0674. PMID: 21364117; PMCID: PMC3046948.
31. Rizk NA, Kanafani ZA, Tabaja HZ, Kanj SS. Extended infusion of beta-lactam antibiotics: optimizing therapy in critically-ill patients in the era of antimicrobial resistance. Expert Rev Anti Infect Ther. 2017 Jul;15(7):645- 652. doi: 10.1080/14787210.2017.1348894. Epub 2017 Jul 3. PMID: 28657373.
32. Lodise TP, Lomaestro BM, Drusano GL; Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2006 Sep;26(9):1320-32. doi: 10.1592/ phco.26.9.1320. PMID: 16945055.
33. Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother. 2005 Jan;49(1):461-3. doi: 10.1128/ AAC.49.1.461-463.2005. PMID: 15616337; PMCID: PMC538854.
34. Kaufman SE, Donnell RW, Hickey WS. Rationale and evidence for extended infusion of piperacillin-tazobactam. Am J Health Syst Pharm. 2011 Aug 15;68(16):1521- 6. doi: 10.2146/ajhp100694. PMID: 21817083.
35. Fawaz S, Barton S, Nabhani-Gebara S. Comparing clinical outcomes of piperacillin-tazobactam administration and dosage strategies in critically ill adult patients: a systematic review and meta-analysis. BMC Infect Dis. 2020 Jun 20;20(1):430. doi: 10.1186/ s12879-020-05149-6. PMID: 32563242; PMCID: PMC7305614.
36. Единая информационная система в сфере закупок. (Режим доступа: https://zakupki.gov.ru/epz/main/pub-lic/home.html (Дата доступа: 20.09.2023).
Review
For citations:
Gomon Yu.M. Piperacillin-tazobactam: prospects for use in real-world practice. Real-World Data & Evidence. 2023;3(3):1-7. (In Russ.) https://doi.org/10.37489/2782-3784-myrwd-36. EDN: CUYJRQ
Views:
1766
Email this article 
Post a Comment 